Protagonist Therapeutics Inc. | Mutual Funds
Mutual Funds that own Protagonist Therapeutics Inc.
Fidelity Growth Company Fund
826,927
3.9%
-4,487
0.02%
07/31/2018
Fidelity Select Biotechnology Portfolio
630,863
2.97%
0
0.07%
07/31/2018
Fidelity Series Small Cap Opportunities Fund
591,900
2.79%
29,300
0.09%
04/30/2018
Vanguard Total Stock Market Index Fund
316,162
1.49%
0
0%
07/31/2018
Fidelity Series Growth Company Fund
262,138
1.24%
0
0.02%
07/31/2018
Fidelity Advisor Biotechnology Fund
174,423
0.82%
0
0.06%
07/31/2018
Fidelity Stock Selector Small Cap Fund
173,100
0.82%
8,700
0.13%
04/30/2018
Vanguard Extended Market Index Fund
164,331
0.77%
800
0%
07/31/2018
American Century Small Company Fund
77,868
0.37%
0
0.11%
06/30/2018
CREF Stock Account
71,780
0.34%
6,406
0%
03/31/2018
| Address |
7707 Gateway Boulevard
Newark California 94560
United States
|
|
Employees
|
- |
| Website |
http://www.protagonist-inc.com |
| Updated |
07/08/2019 |
| Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. |
